AMRX - Amneal Pharmaceuticals Inc Stock Price, Fair Value and News

6.82USD+0.07 (+1.04%)Delayed

Market Summary

USD6.82+0.07

Delayed

1.04%

AMRX Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

AMRX Stock Price

View Fullscreen

AMRX RSI Chart

AMRX Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-13.56

Price/Sales (Trailing)

0.84

EV/EBITDA

40.32

Price/Free Cashflow

13.26

AMRX Price/Sales (Trailing)

AMRX Profitability

EBT Margin

-4.26%

Return on Equity

244.03%

Return on Assets

-4.49%

Free Cashflow Yield

7.54%

AMRX Fundamentals

AMRX Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

18.23%

Rev. Growth (Qtr)

6.84%

AMRX Earnings

Earnings (TTM)

-155.3M

Earnings Growth (Yr)

-486.29%

Earnings Growth (Qtr)

9.63%

Breaking Down AMRX Revenue

Last 7 days

2.4%

Last 30 days

24.9%

Last 90 days

15.6%

Trailing 12 Months

203.1%

How does AMRX drawdown profile look like?

AMRX Financial Health

Current Ratio

1.65

Debt/Equity

-37.37

Debt/Cashflow

0.08

AMRX Investor Care

Shares Dilution (1Y)

102.91%

Diluted EPS (TTM)

-0.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.5B	0	0	0
2023	2.3B	2.3B	2.4B	2.4B
2022	2.1B	2.1B	2.1B	2.2B
2021	2.0B	2.1B	2.1B	2.1B
2020	1.7B	1.7B	1.9B	2.0B
2019	1.8B	1.8B	1.7B	1.6B
2018	1.1B	1.2B	1.5B	1.7B
2017	1.0B	1.0B	1.0B	1.0B
2016	0	0	0	1.0B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amneal Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	konidaris tasos	sold (taxes)	-163,495	5.31	-30,790	executive vice president & cfo
Mar 12, 2024	konidaris tasos	acquired	-	-	87,720	executive vice president & cfo
Mar 03, 2024	shah nikita	sold (taxes)	-225,008	5.47	-41,135	executive vice president
Mar 03, 2024	konidaris tasos	sold (taxes)	-197,046	5.47	-36,023	executive vice president & cfo
Mar 03, 2024	boyer andrew s	sold (taxes)	-243,754	5.47	-44,562	executive vice president
Mar 03, 2024	boyer andrew s	acquired	-	-	88,945	executive vice president
Mar 03, 2024	daly jason b.	acquired	-	-	60,871	svp, chief legal officer
Mar 03, 2024	shah nikita	acquired	-	-	82,103	executive vice president
Mar 03, 2024	daly jason b.	sold (taxes)	-98,624	5.47	-18,030	svp, chief legal officer
Mar 03, 2024	konidaris tasos	acquired	-	-	102,629	executive vice president & cfo

Which funds bought or sold AMRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	5.44	37,143	742,374	-%
May 16, 2024	COMERICA BANK	reduced	-27.91	-2,134	5,480	-%
May 16, 2024	Virtus Investment Advisers, Inc.	reduced	-42.2	-153,309	209,131	0.15%
May 16, 2024	JANE STREET GROUP, LLC	added	15.52	104,916	789,260	-%
May 15, 2024	Aquatic Capital Management LLC	new	-	435,714	435,714	0.01%
May 15, 2024	MORGAN STANLEY	added	116	3,108,410	5,793,130	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	reduced	-13.74	-337,211	2,092,200	0.01%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	6.76	30,000	493,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	21.59	236,387	1,341,290	-%
May 15, 2024	Centiva Capital, LP	new	-	349,577	349,577	0.01%

Are Funds Buying or Selling AMRX?

Are funds buying AMRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMRX

No. of Funds

Unveiling Amneal Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	patel tushar bhikhubhai	17.4%	53,578,209	SC 13D/A
Apr 24, 2024	fosun international ltd	2.4%	7,558,303	SC 13G/A
Feb 13, 2024	vanguard group inc	4.45%	13,642,387	SC 13G/A
Jan 05, 2024	mahesh akram	9.%	30,384,769	SC 13G
Jan 03, 2024	patel gautam	0.07%	2,025,454	SC 13D/A
Dec 12, 2023	fosun international ltd	5.4%	16,438,356	SC 13G/A
Dec 01, 2023	patel gautam	11.1%	33,885,406	SC 13D/A
Nov 08, 2023	patel dipan	8.8%	26,905,073	SC 13D/A
Nov 08, 2023	patel tushar bhikhubhai	17.5%	53,578,209	SC 13D/A
Nov 08, 2023	patel chintu	8.3%	25,318,839	SC 13D/A

Recent SEC filings of Amneal Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	144	Notice of Insider Sale Intent
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading

Peers (Alternatives to Amneal Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Amneal Pharmaceuticals Inc News

Latest updates

Amneal Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	6.8%	659	617	620	599	558	610	546	559	498	537	529	535	493	510	519	465	499	397	378	405	446
Gross Profit	25.4%	238	190	233	220	178	215	194	201	175	166	199	212	192	167	134	144	183	110	54.00	105	83.00
S&GA Expenses	3.3%	113	109	113	106	102	102	100	99.00	99.00	97.00	91.00	86.00	91.00	85.00	83.00	81.00	78.00	74.00	64.00	67.00	84.00
R&D Expenses	-14.7%	39.00	46.00	41.00	38.00	39.00	42.00	50.00	51.00	53.00	52.00	49.00	53.00	48.00	53.00	45.00	46.00	36.00	48.00	38.00	48.00	54.00
EBITDA Margin	-30.9%	0.04*	0.06*	0.09*	0.08*	-0.04*	-0.05*	-0.06*	-0.07*	0.06*	0.07*	0.08*	0.07*	0.05*	0.05*	0.03*	0.06*	0.05*	-0.04*	-0.01*	-0.01*	-0.13*
Interest Expenses	14.8%	65.00	56.00	48.00	48.00	41.00	51.00	35.00	30.00	27.00	30.00	30.00	32.00	30.00	31.00	31.00	33.00	35.00	37.00	41.00	41.00	40.00
Income Taxes	-37.8%	6.00	10.00	-2.08	-	1.00	-1.80	5.00	7.00	-3.50	4.00	4.00	3.00	0.00	2.00	0.00	2.00	-108	7.00	390	-5.70	-8.43
Earnings Before Taxes	9.5%	-75.52	-83.46	23.00	30.00	-9.43	-7.65	2.00	-232	-9.92	-16.32	-2.04	35.00	15.00	-5.48	-21.89	-21.76	13.00	-57.11	26.00	-56.23	-133
EBT Margin	-153.4%	-0.04*	-0.02*	0.01*	0.01*	-0.11*	-0.11*	-0.12*	-0.12*	0.00*	0.01*	0.02*	0.01*	-0.02*	-0.02*	-0.05*	-0.02*	-0.04*	-0.14*	-0.10*	-0.10*	-0.21*
Net Income	9.6%	-91.64	-101	16.00	22.00	-15.63	-12.03	-7.61	-242	-8.82	-21.80	-7.78	30.00	13.00	-6.83	-21.64	-24.16	120	-64.90	-265	-16.90	-47.88
Net Income Margin	-87.9%	-0.06*	-0.03*	0.00*	-0.01*	-0.12*	-0.12*	-0.13*	-0.13*	0.00*	0.01*	0.01*	0.01*	-0.02*	0.03*	0.01*	-0.13*	-0.13*	-0.24*	-0.20*	-0.04*	-0.16*
Free Cashflow	-110.8%	-13.61	126	70.00	-23.35	130	-34.76	74.00	-130	110	46.00	72.00	-59.74	136	76.00	34.00	171	42.00	-55.41	127	9.00	-126

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.5%	3,456	3,473	3,687	3,701	3,627	3,799	3,874	4,041	3,889	3,940	3,974	4,023	3,960	4,006	4,038	4,057	4,391	3,666	3,704	4,262	4,385
Current Assets	0.2%	1,380	1,378	1,456	1,422	1,307	1,412	1,420	1,554	1,390	1,520	1,570	1,563	1,560	1,552	1,544	1,481	1,774	1,210	1,206	1,186	1,268
Cash Equivalents	-43.6%	52.00	92.00	87.00	109	145	26.00	87.00	92.00	210	248	303	278	452	347	281	266	405	153	213	55.00	64.00
Inventory	-1.8%	571	581	576	551	529	531	544	533	512	489	520	523	497	491	476	444	438	381	402	415	448
Net PPE	-1.7%	440	448	452	459	463	470	470	484	501	514	460	468	471	478	462	461	468	478	491	508	514
Goodwill	0.0%	599	599	599	599	599	599	600	601	603	593	566	549	44.00	523	523	527	515	420	420	420	422
Current Liabilities	-1.4%	834	847	761	777	704	753	818	993	602	677	667	673	637	677	668	655	965	550	535	546	600
Long Term Debt	-0.3%	2,378	2,386	2,542	2,549	2,562	2,592	2,607	2,622	2,673	2,680	2,688	2,720	2,728	2,735	2,757	2,765	2,772	2,609	2,614	2,620	2,625
LT Debt, Current	-1.4%	34.00	34.00	31.00	30.00	30.00	30.00	30.00	30.00	31.00	31.00	30.00	30.00	30.00	44.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	2,386	2,542	2,549	2,562	2,592	2,607	2,622	2,673	2,680	2,688	2,720	2,728	2,735	2,757	2,765	2,772	2,609	2,614	2,620	2,625
Shareholder's Equity	-421.7%	-63.63	20.00	331	151	135	298	194	173	407	367	383	390	367	345	348	371	403	347	396	749	800
Retained Earnings	-18.7%	-581	-490	-391	-401	-413	-406	-401	-399	-278	-276	-269	-265	-280	-286	-283	-274	-262	-377	-345	-80.75	-63.84
Additional Paid-In Capital	-0.1%	539	539	715	708	701	692	684	676	667	658	651	643	634	628	623	618	612	607	566	544	537
Shares Outstanding	74.5%	307	176	153	153	152	151	151	151	150	149	149	149	148	147	148	147	147	132	129	128	128
Minority Interest	-58.7%	0.00	0.00	-176	-167	-159	-114	-103	-107	16.00	7.00	33.00	44.00	44.00	42.00	47.00	65.00	85.00	115	178	290	328
Float	-	-	-	-	464	-	-	-	471	-	-	-	751	-	-	-	696	-	-	-	1,202	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-103.2%	-4.41	136	81.00	-11.34	140	-23.29	94.00	-125	120	63.00	82.00	-51.93	148	106	45.00	179	49.00	-50.89	140	21.00	-108
Share Based Compensation	12.5%	7.00	6.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	5.00	5.00	5.00	6.00	5.00	5.00	6.00	6.00	4.00
Cashflow From Investing	37.6%	-19.76	-31.69	-13.48	-12.28	-11.74	-11.47	-49.33	-16.12	-97.39	-86.97	-11.63	-82.89	-12.69	-31.79	-14.78	-8.93	-262	-4.77	30.00	-23.33	-21.47
Cashflow From Financing	77.0%	-23.15	-100	-86.58	-12.26	-12.90	-22.17	-46.13	23.00	-61.57	-30.35	-43.55	-38.07	-26.15	-11.28	-14.81	-310	468	-7.30	-7.60	-9.07	-21.86
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AMRX Income Statement

2024-03-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 659,191	$ 557,540
Cost of goods sold	421,131	379,354
Gross profit	238,060	178,186
Selling, general and administrative	112,595	102,096
Research and development	39,298	38,690
Intellectual property legal development expenses	984	1,644
Restructuring and other charges	1,470	510
Change in fair value of contingent consideration	100	2,457
Charges (credit) related to legal matters, net	94,359	(436)
Other operating income	0	(1,224)
Operating (loss) income	(10,746)	34,449
Other (expense) income:
Interest expense, net	(65,703)	(49,315)
Foreign exchange (loss) gain, net	(1,197)	1,901
Increase in tax receivable agreement liability	(1,948)	(826)
Other income, net	4,072	4,365
Total other expense, net	(64,776)	(43,875)
Loss before income taxes	(75,522)	(9,426)
Provision for income taxes	6,156	668
Net loss	(81,678)	(10,094)
Less: Net (income) loss attributable to non-controlling interests	(9,965)	3,151
Net loss attributable to Amneal Pharmaceuticals, Inc.	$ (91,643)	$ (6,943)
Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic (in dollars per share)	$ (0.30)	$ (0.05)
Diluted (in dollars per share)	$ (0.30)	$ (0.05)
Weighted-average common shares outstanding:
Basic (in shares)	307,279	152,109
Diluted (in shares)	307,279	152,109

AMRX Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 46,520	$ 91,542
Restricted cash	5,097	7,565
Inventories	570,653	581,384
Prepaid expenses and other current assets	87,298	82,685
Total current assets	1,380,044	1,377,863
Property, plant and equipment, net	439,815	447,574
Goodwill	598,549	598,629
Intangible assets, net	859,272	890,423
Other assets	73,747	55,517
Total assets	3,456,397	3,472,569
Current liabilities:
Current portion of liabilities for legal matters	30,130	76,988
Revolving credit facility	179,000	179,000
Current portion of long-term debt, net	33,660	34,125
Total current liabilities	834,388	846,595
Long-term debt, net	2,377,707	2,386,004
Note payable - related party	41,893	41,447
Liabilities for legal matters - long term	85,479	316
Total long-term liabilities	2,638,616	2,564,670
Commitments and contingencies (Notes 4 and 17)
Redeemable non-controlling interests	47,022	41,293
Stockholders' (Deficiency) Equity
Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	538,720	539,240
Stockholders' accumulated deficit	(581,819)	(490,176)
Accumulated other comprehensive loss	(23,711)	(32,349)
Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity	(63,724)	19,781
Non-controlling interests	95	230
Total stockholders' (deficiency) equity	(63,629)	20,011
Total liabilities and stockholders' (deficiency) equity	3,456,397	3,472,569
Related Party
Current assets:
Trade accounts receivable, net	1,521	955
Operating lease right-of-use assets	12,468	12,954
Current liabilities:
Accounts payable and accrued expenses	17,075	7,321
Current portion of operating lease liabilities - related party	3,192	2,825
Operating lease liabilities	11,969	12,787
Other long-term liabilities	11,394	11,776
Nonrelated Party
Current assets:
Trade accounts receivable, net	668,955	613,732
Operating lease right-of-use assets	32,970	30,329
Financing lease right-of-use assets	59,532	59,280
Current liabilities:
Accounts payable and accrued expenses	558,518	534,662
Current portion of operating lease liabilities	9,508	9,207
Current portion of financing lease liabilities	3,305	2,467
Operating lease liabilities	26,786	24,095
Financing lease liabilities	58,809	58,566
Other long-term liabilities	24,579	29,679
Common Class A
Stockholders' (Deficiency) Equity
Common stock	3,086	3,066
Common Class B
Stockholders' (Deficiency) Equity
Common stock	$ 0	$ 0

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

CEO	Mr. Chirag K. Patel
WEBSITE	https://amneal.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	7600

Amneal Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Amneal Pharmaceuticals Inc? What does AMRX stand for in stocks?

AMRX is the stock ticker symbol of Amneal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amneal Pharmaceuticals Inc (AMRX)?

As of Fri May 17 2024, market cap of Amneal Pharmaceuticals Inc is 2.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRX stock?

You can check AMRX's fair value in chart for subscribers.

What is the fair value of AMRX stock?

You can check AMRX's fair value in chart for subscribers. The fair value of Amneal Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amneal Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amneal Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMRX is over valued or under valued. Whether Amneal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amneal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRX.

What is Amneal Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AMRX's PE ratio (Price to Earnings) is -13.56 and Price to Sales (PS) ratio is 0.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRX PE ratio will change depending on the future growth rate expectations of investors.